



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## REQUEST FOR CONTINUED EXAMINATION AND PETITION FOR EXTENSION OF TIME

Attorney Docket No.: 01017/39555

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This is a Request for Continued Examination under 37 C.F.R. §1.114 of the following application:

Application No.

10/694,579

Filing Date

October 27, 2003

Inventor(s)

Mehta et al.

Title

G-CSF Therapy as an Adjunct to Reperfusion Therapy in

the Treatment of Acute Myocardial Infarction

Art Unit

1647

Examiner

James Jason Galvez

#### 1. Submission required under 37 C.F.R. §1.114

x	Previously submitted			
	x	Please enter and consider the amendment(s)/reply under 37 C.F.R. §1.116 previously filed May 20, 2005		
x Enclosed				
	$\begin{bmatrix} \mathbf{x} \end{bmatrix}$	Amendment/Reply		
		Affidavit(s)/Declaration(s)		
		Information disclosure statement		
I hereby certify	that this c	correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Clas-		

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 10, 2005

Lynn L. Janulis, Registration No. 53,066

08/15/2005 MHOLDGE1 00000016 10694579

01 FC:1801

790.00 BP

08/15/2005 MWDLDGE1 00000016 10694579

02 FC:1251

120.00 OP

Application No.: 10/694,579 Docket No.: 01017/39555

2.	Misc	Miscellaneous					
	x	This is a petition for a 1 -month extension of time.					
	Suspension of action on the above-identified application is requested C.F.R. § 1.103(c) for a period of months.  (Suspension period not to exceed 3 months; fee under 37. C.F.R. § 1.17(I) required).						
		Other:					
3.	Fees						
	$\begin{bmatrix} \mathbf{x} \end{bmatrix}$	RCE fee required under 37 C.F.R. §1.17(e)	\$	790.00			
	$\mathbf{x}$	Extension of time fee under 37 C.F.R. §1.17(a)	\$	120.00			
		Other:	\$				
4.	Meth	od of Payment of Fees					
	$\mathbf{x}$	Enclosed is a check in the amount of:	\$	910.00			
		Charge Deposit Account No. 13-2855 in the amount of: A copy of this transmittal is enclosed.	\$				

The Director is hereby authorized to charge any fee which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 01017/39555. A copy of this paper is enclosed.

Please direct all future communications to Marshall, Gerstein & Borun LLP at the address below.

Dated: August 10, 2005

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

Lynn L. Janulis

Registration No.: 53,066


Agent for Applicants

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300



APPLICATION NO. 10/694,579 ATTORNEY DOCKET NO. 01017/39555

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Mehta et al.	) For: G-CSF Therapy as an Adjunct to
Application No: 10/694,579	<ul><li>) Reperfusion Therapy in the Treatment of</li><li>) Acute Myocardial Infarction</li></ul>
Filed: October 27, 2003	) Group Art Unit: 1647
	) Examiner: James Jason Galvez

# AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111 ACCOMPANYING REQUEST FOR CONTINUING EXAMINATION UNDER 37 C.F.R. §1.114

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This paper accompanies a Request for Continuing Examination (RCE) submitted herewith under 37 C.F.R. §1.114 and is in response to an Advisory Action mailed July 15, 2005. Please enter the amendment filed on May 20, 2005 along with the present amendment. Reconsideration and withdrawal of the rejections is respectfully solicited for the reasons set out in the amendment filed on May 20, 2005 along with present amendment. This response is timely filed as it is accompanied by a petition for an extension of time and the requisite fee.

Please amend the above-identified application as follows:

Amendments to the Specification: none.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.